Reports Q1 revenue $225,000, consensus $7.5M. “We are entering a catalyst-rich period for Tenaya, with multiple clinical milestones expected across our lead gene therapy programs throughout 2026. Building on the encouraging initial readouts we reported in 2025, we believe the additional data expected this year from both TN-201 and TN-401 may support alignment on registrational pathways for these novel gene therapies,” said Faraz Ali, Chief Executive Officer of Tenaya.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNYA:
- Tenaya Therapeutics Duchenne muscular dystrophy treatment granted orphan status
- Tenaya’s TN-401: Differentiated PKP2 Gene Therapy Opportunity Underpins Favorable Risk–Reward and Buy Rating
- Advancing Pipeline and Regulatory Clarity Underpin Buy Rating on Tenaya Therapeutics
- Tenaya Therapeutics: Early Gene Therapy Promise, Cash Runway to 2H27, and 2026 Data Catalysts Support Buy Rating and $5 Target
- Tenaya Therapeutics: Gene Therapy Momentum and De‑Risking Clinical Milestones Support Buy Rating